Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review

被引:21
作者
Giron Moreno, Rosa Maria [1 ]
Garcia-Clemente, Marta [2 ]
Diab-Caceres, Layla [3 ]
Martinez-Vergara, Adrian [4 ]
Martinez-Garcia, Miguel Angel [5 ]
Gomez-Punter, Rosa Mar [1 ]
机构
[1] Inst Invest Sanitaria La Princesa, Serv Neumol, Madrid 28006, Spain
[2] Hosp Univ Cent Asturias, Serv Neumol, C Ave Roma S-N, Oviedo 33011, Spain
[3] Hosp Univ 12 Octubre, Serv Neumol, Madrid 28041, Spain
[4] Hosp Univ Princesa, Serv Neumol, Madrid 28006, Spain
[5] Univ Valencia, Hosp Fe, CIBER Enfermedades Resp, Valencia 46026, Spain
来源
ANTIBIOTICS-BASEL | 2021年 / 10卷 / 05期
关键词
cystic fibrosis; treatment; inflammation; obstruction; antibiotic; CFTR modulator; genetic therapy; RNA therapy; editing gene; PSEUDOMONAS-AERUGINOSA COLONIZATION; INHALED AZTREONAM LYSINE; RECOMBINANT HUMAN DNASE; LONG-TERM AZITHROMYCIN; HIGH-DOSE IBUPROFEN; QUALITY-OF-LIFE; LUNG-DISEASE; DOUBLE-BLIND; TEZACAFTOR-IVACAFTOR; ANTIBIOTIC-TREATMENT;
D O I
10.3390/antibiotics10050486
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Cystic fibrosis (CF) is a genetic disease that causes absence or dysfunction of a protein named transmembrane conductance regulatory protein (CFTR) that works as an anion channel. As a result, the secretions of the organs where CFTR is expressed are very viscous, so their functionality is altered. The main cause of morbidity is due to the involvement of the respiratory system as a result of recurrent respiratory infections by different pathogens. In recent decades, survival has been increasing, rising by around age 50. This is due to the monitoring of patients in multidisciplinary units, early diagnosis with neonatal screening, and advances in treatments. In this chapter, we will approach the different therapies used in CF for the treatment of symptoms, obstruction, inflammation, and infection. Moreover, we will discuss specific and personalized treatments to correct the defective gene and repair the altered protein CFTR. The obstacle for personalized CF treatment is to predict the drug response of patients due to genetic complexity and heterogeneity of uncommon mutations.
引用
收藏
页数:41
相关论文
共 229 条
[1]   Duration of intravenous antibiotic therapy in people with cystic fibrosis [J].
Abbott, Linsey ;
Plummer, Amanda ;
Hoo, Zhe Hui ;
Wildman, Martin .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (09)
[2]   The pharmacokinetics of antibiotics in cystic fibrosis [J].
Akkerman-Nijland, Anne M. ;
Akkerman, Onno W. ;
Grasmeijer, Floris ;
Hagedoorn, Paul ;
Frijlink, Henderik. W. ;
Rottier, Bart. L. ;
Koppelman, Gerard. H. ;
Touw, Daniel. J. .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (01) :53-68
[3]   Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin [J].
Akkerman-Nijland, Anne M. ;
Yousofi, Mina ;
Rottier, Bart L. ;
Van der Vaart, Hester ;
Burgerhof, Johannes G. M. ;
Frijlink, Henderik W. ;
Touw, Daan J. ;
Koppelman, Gerard H. ;
Akkerman, Onno W. .
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2020, 14
[4]  
Alton E.W.F.W, 2016, NIHR J LIB SOUTHAMPT
[5]  
Amin R., 2012, TRATADO FIBROSIS QU, P243
[6]  
[Anonymous], UK CYST FIBR TRUST
[7]   Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial [J].
Assael, Baroukh M. ;
Pressler, Tacjana ;
Bilton, Diana ;
Fayon, Michael ;
Fischer, Rainald ;
Chiron, Raphael ;
LaRosa, Mario ;
Knoop, Christiane ;
McElvaney, Noel ;
Lewis, Sandra A. ;
Bresnik, Mark ;
Montgomery, A. Bruce ;
Oermann, Christopher M. .
JOURNAL OF CYSTIC FIBROSIS, 2013, 12 (02) :130-140
[8]   Bronchial Infection due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis Diagnosed in Neonatal Screening [J].
Ayats Vidal, Roser ;
Bosque Garcia, Montserrat ;
Garcia Gonzalez, Miguel ;
Asensio de la Cruz, Oscar .
ARCHIVOS DE BRONCONEUMOLOGIA, 2020, 56 (08) :532-534
[9]   Role of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic Fibrosis [J].
Balazs, Anita ;
Mall, Marcus A. .
FRONTIERS IN PHARMACOLOGY, 2018, 9
[10]   Inhaled corticosteroids for cystic fibrosis [J].
Balfour-Lynn, Ian M. ;
Welch, Karen .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (08)